411 related articles for article (PubMed ID: 22282465)
1. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
Miranda C; Nucifora M; Molinari F; Conca E; Anania MC; Bordoni A; Saletti P; Mazzucchelli L; Pilotti S; Pierotti MA; Tamborini E; Greco A; Frattini M
Clin Cancer Res; 2012 Mar; 18(6):1769-76. PubMed ID: 22282465
[TBL] [Abstract][Full Text] [Related]
2. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of an Italian series of sporadic GISTs.
Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
[TBL] [Abstract][Full Text] [Related]
4. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
6. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
7. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
9. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
10. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
13. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC; Corless CL; Demetri GD; Blanke CD; von Mehren M; Joensuu H; McGreevey LS; Chen CJ; Van den Abbeele AD; Druker BJ; Kiese B; Eisenberg B; Roberts PJ; Singer S; Fletcher CD; Silberman S; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2003 Dec; 21(23):4342-9. PubMed ID: 14645423
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
16. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.
Quattrone A; Wozniak A; Dewaele B; Floris G; Vanspauwen V; Van Looy T; Schöffski P; Rutkowski P; Sciot R; Debiec-Rychter M
Mod Pathol; 2014 Nov; 27(11):1510-20. PubMed ID: 24743220
[TBL] [Abstract][Full Text] [Related]
17. [Translational research and diagnosis in GIST].
Wardelmann E
Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
[TBL] [Abstract][Full Text] [Related]
18. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
19. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
20. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
